Hansoh Pharma receives approval for Hengmeida in China

Hansoh Pharmaceutical Group Company Limited (HKEX:3692) announced today that its drug Hengmeida (Ibrexafungerp Tablets) has received registration approval from the National Medical Products Administration (NMPA) of China. The approval allows for the treatment of vulvovaginal candidiasis (VVC) in adult and post-menarche adolescent women. This voluntary announcement highlights a significant milestone for Hansoh Pharma in expanding its pharmaceutical offerings within the Chinese market. The board of directors expressed their satisfaction with this development, indicating a positive outlook for the company's growth.